Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.

[1]  E. Winer,et al.  Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. , 2021, The Lancet. Oncology.

[2]  P. Neven,et al.  Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Berry,et al.  Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. , 2020, JAMA oncology.

[4]  W. Symmans,et al.  Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. , 2020, Clinical chemistry.

[5]  A. Viale,et al.  SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer , 2019, npj Breast Cancer.

[6]  D. Berry,et al.  MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Cuzick,et al.  Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer , 2018, JAMA oncology.

[8]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[9]  D. Berry,et al.  Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial , 2017 .

[10]  D. Berry,et al.  Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial , 2017 .

[11]  Mei Liu,et al.  Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Michael Hogarth,et al.  Adaptive Randomization of Neratinib in Early Breast Cancer. , 2016, The New England journal of medicine.

[13]  Anne M Wallace,et al.  Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. , 2016, The New England journal of medicine.

[14]  M. Buyse,et al.  Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  N. Hylton,et al.  Abstract P1-14-03: The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL , 2016 .

[16]  E. Mardis,et al.  PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) , 2016, npj Breast Cancer.

[17]  E. Perez,et al.  Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jack Cuzick,et al.  Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. , 2013, The Lancet. Oncology.

[19]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  John Quackenbush,et al.  A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.

[21]  J. Cuzick,et al.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Buyse,et al.  Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[24]  Peter Regitnig,et al.  Genomic index of sensitivity to endocrine therapy for breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Metzler,et al.  Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer , 2010, Breast Cancer Research and Treatment.

[26]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Marek Pawlicki,et al.  Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.

[29]  Douglas G Altman,et al.  Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.

[30]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.